We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should You Continue to Retain Bruker Stock in Your Portfolio?
Read MoreHide Full Article
Key Takeaways
Bruker's BSI Nano unit shows strong growth, aided by AI-driven semiconductor metrology demand.
BRKR is expanding BioSpin with acquisitions, lab automation and advanced imaging innovations.
Bruker faces macro pressures, tariffs and an 8% currency headwind to 2026 EPS.
Bruker Corporation (BRKR - Free Report) appears well-positioned for growth in the coming quarters due to its solid prospects in Bruker Scientific Instruments (“BSI”) Nano, supported by strong innovations and AI-driven demand. The company is steadily advancing its BioSpin offerings, targeting applications in structural proteomics, drug discovery, research, and food and materials science fields. Its financial health further adds to the stock’s appeal. Meanwhile, operational headwinds from macroeconomic pressures and currency fluctuations remain a concern for Bruker.
In the past year, this Zacks Rank #3 (Hold) stock has declined 4.2%, similar to its industry. The S&P 500 composite, however, has risen 24.7%.
The renowned medical device company has a market capitalization of $5.50 billion. Bruker’s estimated earnings growth for 2027 stands at 13.7% compared with the industry’s 12.9% growth. In the trailing four quarters, it surpassed earnings estimates twice and missed on two occasions, the average surprise being 6.57%.
Let’s delve deeper.
Upsides for BRKR Stock
BSI Nano Group’s Prospects Bright: The business is seeing robust revenue growth across its end markets, including academic, government, industrial and semiconductor metrology. Bruker has broadened its spatial transcriptomics and gene expression analysis capabilities by acquiring most of NanoString Technologies’ assets and also Nion. The segment houses Bruker Cellular Analysis (formerly Phenomex), complementing its cellular and sub-cellular analysis tools, including the CellScape spatial biology platform.
Bruker is gaining from the AI boom indirectly, with its semiconductor metrology tools for new nodes and advanced packaging seeing solid order growth, particularly in the fourth quarter. Recent innovations in the segment include an EBSD detector for ultra-fast and ultra-sensitive characterization of crystalline materials in electron microscopes, an X-ray µCT system and advancements to imaging-based or digital readout platforms for spatial biology applications.
Image Source: Zacks Investment Research
Robust Prospects for BioSpin: Bruker strengthened the segment with the 2024 acquisition of Chemspeed Technologies AG, accelerating its entry into lab automation, digitalization and scientific software solutions. The addition of Spectral Instruments Imaging enhanced the Preclinical Imaging portfolio with in vivo optical imaging. Throughout 2025, the company continued to focus on enhancing customer relationships and driving innovation with its key initiatives, including expansion into high-potential markets, leveraging core strengths, and driving recurring revenues through aftermarket and connected services.
On the innovation front, Bruker introduced the Dynamic Nuclear Polarization (d-DNP) Polarizer this year, and also developed and tested the world’s first high-resolution 1.3 GHz NMR spectrometer with a stable, standard-bore 54 mm superconducting magnet. Bruker completed certain minority investments, which align with the segment’s goals of expanding its technological capabilities, entering new markets and enhancing its product portfolio.
Strong Solvency but Leveraged Balance Sheet: At the end of the fourth quarter of 2025, Bruker reported cash and cash equivalents of $298.8 million and only $17 million in short-term debt. Long-term debt dropped 6.6% from the previous quarter, reaching $1.86 billion. The debt-to-capital ratio was 43% compared with 45.1% at the end of the third quarter.
What Ails Bruker?
Macroeconomic Factors: Bruker’s operations are exposed to the macroeconomic challenges, including ongoing geopolitical tensions in Russia, Ukraine and the Middle East. New U.S. tariffs imposed have had a material adverse effect on its business, results of operations and financial condition. Supply-chain risks tied to inflation, recession risks, currency volatility, and the global shortage of semiconductor chips, components and raw materials such as copper also persist. These elevated costs and expenses are squeezing margins and putting pressure on profitability.
Exposed to Currency Movement: Bruker generates a substantial portion of its revenues in the international markets, primarily in Germany and other countries in the European Union, Switzerland and Japan. As a result, currency fluctuations continue to result in foreign currency transaction losses at the company. Currency fluctuations could cause the price of Bruker’s products to be less competitive than its principal competitors' offerings. At current rates, management expects an approximately 8% currency headwind to fiscal 2026 earnings per share (EPS).
BRKR Stock Estimate Trend
Going by the Zacks Consensus Estimate, Bruker’s 2026 EPS is projected to increase 15.3% to $2.11. The estimate has remained constant in the past 30 days.
The consensus mark for 2026 revenues is pegged at $3.59 billion. This suggests a 4.3% rise from the year-ago reported number.
Globus Medical has an earnings yield of 5.3%, well ahead of the industry’s -1% yield. Its earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 18.8%. The company’s shares have rallied 13.8% against the industry’s 3.8% fall in the past year.
Envista, sporting a Zacks Rank #1 at present, has an earnings yield of 5.7% compared with the industry’s 2.7% yield. Shares of the company have soared 41.9% against the industry’s 21.9% decline. NVST’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.4%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy), has an earnings yield of 2.1% against the industry’s 0.7% decline. Shares of the company have dropped 8.8% compared with the industry’s 3.8% fall. ISRG’s earnings topped estimates in each of the trailing four quarters, the average surprise being 13.2%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Should You Continue to Retain Bruker Stock in Your Portfolio?
Key Takeaways
Bruker Corporation (BRKR - Free Report) appears well-positioned for growth in the coming quarters due to its solid prospects in Bruker Scientific Instruments (“BSI”) Nano, supported by strong innovations and AI-driven demand. The company is steadily advancing its BioSpin offerings, targeting applications in structural proteomics, drug discovery, research, and food and materials science fields. Its financial health further adds to the stock’s appeal. Meanwhile, operational headwinds from macroeconomic pressures and currency fluctuations remain a concern for Bruker.
In the past year, this Zacks Rank #3 (Hold) stock has declined 4.2%, similar to its industry. The S&P 500 composite, however, has risen 24.7%.
The renowned medical device company has a market capitalization of $5.50 billion. Bruker’s estimated earnings growth for 2027 stands at 13.7% compared with the industry’s 12.9% growth. In the trailing four quarters, it surpassed earnings estimates twice and missed on two occasions, the average surprise being 6.57%.
Let’s delve deeper.
Upsides for BRKR Stock
BSI Nano Group’s Prospects Bright: The business is seeing robust revenue growth across its end markets, including academic, government, industrial and semiconductor metrology. Bruker has broadened its spatial transcriptomics and gene expression analysis capabilities by acquiring most of NanoString Technologies’ assets and also Nion. The segment houses Bruker Cellular Analysis (formerly Phenomex), complementing its cellular and sub-cellular analysis tools, including the CellScape spatial biology platform.
Bruker is gaining from the AI boom indirectly, with its semiconductor metrology tools for new nodes and advanced packaging seeing solid order growth, particularly in the fourth quarter. Recent innovations in the segment include an EBSD detector for ultra-fast and ultra-sensitive characterization of crystalline materials in electron microscopes, an X-ray µCT system and advancements to imaging-based or digital readout platforms for spatial biology applications.
Image Source: Zacks Investment Research
Robust Prospects for BioSpin: Bruker strengthened the segment with the 2024 acquisition of Chemspeed Technologies AG, accelerating its entry into lab automation, digitalization and scientific software solutions. The addition of Spectral Instruments Imaging enhanced the Preclinical Imaging portfolio with in vivo optical imaging. Throughout 2025, the company continued to focus on enhancing customer relationships and driving innovation with its key initiatives, including expansion into high-potential markets, leveraging core strengths, and driving recurring revenues through aftermarket and connected services.
On the innovation front, Bruker introduced the Dynamic Nuclear Polarization (d-DNP) Polarizer this year, and also developed and tested the world’s first high-resolution 1.3 GHz NMR spectrometer with a stable, standard-bore 54 mm superconducting magnet. Bruker completed certain minority investments, which align with the segment’s goals of expanding its technological capabilities, entering new markets and enhancing its product portfolio.
Strong Solvency but Leveraged Balance Sheet: At the end of the fourth quarter of 2025, Bruker reported cash and cash equivalents of $298.8 million and only $17 million in short-term debt. Long-term debt dropped 6.6% from the previous quarter, reaching $1.86 billion. The debt-to-capital ratio was 43% compared with 45.1% at the end of the third quarter.
What Ails Bruker?
Macroeconomic Factors: Bruker’s operations are exposed to the macroeconomic challenges, including ongoing geopolitical tensions in Russia, Ukraine and the Middle East. New U.S. tariffs imposed have had a material adverse effect on its business, results of operations and financial condition. Supply-chain risks tied to inflation, recession risks, currency volatility, and the global shortage of semiconductor chips, components and raw materials such as copper also persist. These elevated costs and expenses are squeezing margins and putting pressure on profitability.
Exposed to Currency Movement: Bruker generates a substantial portion of its revenues in the international markets, primarily in Germany and other countries in the European Union, Switzerland and Japan. As a result, currency fluctuations continue to result in foreign currency transaction losses at the company. Currency fluctuations could cause the price of Bruker’s products to be less competitive than its principal competitors' offerings. At current rates, management expects an approximately 8% currency headwind to fiscal 2026 earnings per share (EPS).
BRKR Stock Estimate Trend
Going by the Zacks Consensus Estimate, Bruker’s 2026 EPS is projected to increase 15.3% to $2.11. The estimate has remained constant in the past 30 days.
The consensus mark for 2026 revenues is pegged at $3.59 billion. This suggests a 4.3% rise from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Envista (NVST - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Globus Medical has an earnings yield of 5.3%, well ahead of the industry’s -1% yield. Its earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 18.8%. The company’s shares have rallied 13.8% against the industry’s 3.8% fall in the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Envista, sporting a Zacks Rank #1 at present, has an earnings yield of 5.7% compared with the industry’s 2.7% yield. Shares of the company have soared 41.9% against the industry’s 21.9% decline. NVST’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.4%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy), has an earnings yield of 2.1% against the industry’s 0.7% decline. Shares of the company have dropped 8.8% compared with the industry’s 3.8% fall. ISRG’s earnings topped estimates in each of the trailing four quarters, the average surprise being 13.2%.